Prolactin-Secreting Leiomyoma Causing Hyperprolactinaemia Unresponsive to Dopamine Agonist Therapy and Resolution following Myomectomy.


Journal

Case reports in endocrinology
ISSN: 2090-6501
Titre abrégé: Case Rep Endocrinol
Pays: United States
ID NLM: 101576457

Informations de publication

Date de publication:
2021
Historique:
received: 03 03 2021
accepted: 30 08 2021
entrez: 20 9 2021
pubmed: 21 9 2021
medline: 21 9 2021
Statut: epublish

Résumé

Prolactin-secreting leiomyomas are rare, with only eight cases reported in the literature. This case describes a 37-year-old female with hyperprolactinaemia (1846 mIU/L; 85-500 mIU/L) refractory to cabergoline causing infertility and galactorrhea. MRI pituitary was normal. The patient had a known enlarging uterine leiomyoma on serial pelvic ultrasounds (15.2 cm × 9.1 cm × 12.1 cm). The serum prolactin returned to subnormal levels two days postmyomectomy and showed recovery to normal levels in the months following surgery. Immunostaining of the leiomyoma for prolactin was negative. Despite not staining for prolactin, quick resolution of the patient's hyperprolactinaemia after myomectomy supports the diagnosis of a prolactin-secreting fibroid. A prolactin-secreting leiomyoma should be considered in patients with hyperprolactinaemia and normal pituitary MRI which is refractory to dopamine receptor agonist therapy who also have evidence of a uterine fibroid. In patients wishing to seek fertility, myomectomy should be considered to allow for normal ovulation and possibility of future fertility.

Identifiants

pubmed: 34540295
doi: 10.1155/2021/5553187
pmc: PMC8445707
doi:

Types de publication

Case Reports

Langues

eng

Pagination

5553187

Informations de copyright

Copyright © 2021 Lucinda Barry et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Références

Reprod Biomed Online. 2008 Oct;17(4):569-74
pubmed: 18854113
Gynecol Obstet Invest. 1999;48(2):127-32
pubmed: 10461005
Neurology. 2000 Jul 12;55(1):148-9
pubmed: 10891931
Aust Fam Physician. 2016 Oct;45(10):722-725
pubmed: 27695721
Mol Endocrinol. 2014 May;28(5):622-33
pubmed: 24694306
Mol Cell Endocrinol. 1991 Jan;75(1):71-80
pubmed: 2050267
J Neurosurg. 2019 Jun 14;:1-8
pubmed: 31200381
Front Endocrinol (Lausanne). 2020 Oct 09;11:594370
pubmed: 33162942
J Endocr Soc. 2020 Mar 16;4(4):bvaa035
pubmed: 32296740
J Obstet Gynaecol. 2019 Oct;39(7):1034-1036
pubmed: 31195872
Gynecol Endocrinol. 2012 Feb;28(2):148-9
pubmed: 21780951
Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:74-78
pubmed: 27639604
Ann Hematol. 2005 Mar;84(3):200-2
pubmed: 15599545
Saudi Med J. 2008 Nov;29(11):1593-6
pubmed: 18998007
Pituitary. 2020 Dec;23(6):641-647
pubmed: 32857272
Gynecol Endocrinol. 2018 Mar;34(3):199-201
pubmed: 28925774

Auteurs

Lucinda Barry (L)

Royal Prince Alfred Hospital, Sydney, Australia.

Selvan Pather (S)

Chris O'Brien Lifehouse, Sydney, Australia.

Ash Gargya (A)

Royal Prince Alfred Hospital, Sydney, Australia.

Anthony Marren (A)

Royal Prince Alfred Hospital, Sydney, Australia.

Classifications MeSH